^
Association details:
| Biomarker: | HER-2 L768S |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Excerpt:
Trastuzumab and lapatinib treatment significantly decreased the number of colonies formed by MCF10A cells bearing HER2 L768S or V773L mutation but did not significantly reduce the number of colonies formed by MCF10A cells with HER2 K753E mutation. While L768S and V773L have similar colony number with K753E after being treated with trastuzumab and lapatinib, the drugs significantly decreased the number of colonies formed, and we conclude that L768S and V773L mutations were sensitive toward trastuzumab and lapatinib treatment.
DOI:
https://doi.org/10.1158/1078-0432.CCR-15-3036
